Bicycle Therapeutics Narrows Q3 Loss to $10.5M as Bayer Revenue Lifts Top Line
BCYC sits 16% above its 52-week low of $3.33.
Summary
Bicycle Therapeutics posted a Q3 net loss of $10.5 million, or $0.15 per share, versus a $59.1 million loss a year earlier. Collaboration revenue jumped to $34.1 million from $11.7 million, driven by recognizing all remaining revenue under the terminated Bayer agreement — a one-time boost, not recurring. R&D fell to $33.4 million from $58.4 million after the August 2025 and March 2026 workforce cuts, and G&A dropped to $14.1 million from $18.9 million. Cash stood at $469.9 million at September 30, down from $628.1 million at year-end 2025, still a substantial runway for a company this size. The FDA granted Orphan Drug Designation to nuzefatide in pancreatic cancer in September, and the company expects Duravelo-2 survival data and its first company-sponsored BT1702 radioligand trial in the second half of 2027.
At the time of this announcement, BCYC was trading at $3.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $270.9M. The 52-week trading range was $3.33 to $9.08. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.